Contract Manufacturing, Biopharmaceutical Production

Polysorbates: Part(icle) of the Problem?

May 05, 2024

A comparison between polysorbates and HPβCD determines the better stabilizer for biologics formulation.

SK pharmteco to Ensure Supply of Ferring Pharmaceuticals Gene Therapy

April 27, 2024

SK pharmteco, a CDMO, will manufacture, test, and release Adstiladrin (nadofaragene firadenovec-vncg), a gene therapy from Ferring Pharmaceuticals for treating bladder cancer.

Lonza Forms Agreement to Manufacture Acumen Pharmaceuticals’ AD mAb Therapy

April 05, 2024

Under a collaboration agreement, Lonza will manufacture sabirnetug, Acumen Pharmaceuticals' mAb in clinical development for treating Alzheimer’s disease.

FDA Greenlights Orchard Therapeutics' Gene Therapy for Children's MLD; AGC Biologics Selected for Manufacturing

March 20, 2024

FDA's approval makes Orchard Therapeutics' Lenmeldy (atidarsagene autotemcel) the first gene therapy approved to treat pediatric metachromatic leukodystrophy in the US.

Chime Biologics to Manufacture Novel Antibody Cancer Immunotherapy for Domain Therapeutics

March 14, 2024

In a new manufacturing pact, Chime Biologics will produce DT-7012, Domain Therapeutics' antibody candidate for treating cancer that will soon be entering Phase I studies.

Cellares Set to Launch Good Manufacturing Practice–Compliant Cell Shuttle Manufacturing Platform

March 12, 2024

The Cell Shuttle platform will manufacture cell therapies for its first clinical trials by the end of the year.

Cellares Innovates With Automated Cell and Gene Therapy Platform

March 07, 2024

Cellares CEO Fabian Gerlinghaus shares how an automated, closed-production platform with a small footprint can dramatically impact cost savings and scalability for cell and gene therapies.

CordenPharma Expands Clinical Peptide Capacity

March 06, 2024

The company is expanding GMP capacities at its Frankfurt site to manufacture early clinical-phase peptide APIs.

Simtra BioPharma Solutions Expands Sterile Fill/Finish Manufacturing Site

February 28, 2024

The company is investing more than $250 million into its Bloomington, Ind. Manufacturing site.

CSL Licenses Cytegrity Lentiviral Vector Production System to Genezen

February 27, 2024

CSL will share access to Cytegrity, its proprietary stable production system for lentiviral vector production, with Genezen.